rs11650354 — TBX21 TBX21 Region Variant

TBX21 Region Variant — A Second Brake on the T-bet Th1 Program

Inside every naive T cell, the T-bet transcription factor¹¹ T-bet transcription factor
encoded by TBX21 (T-box transcription factor 21); the master regulator of Th1 cell differentiation; activates interferon-gamma and physically represses the Th2 regulators GATA3 and IL-4 sets the immune system's allergic thermostat. When T-bet activity is high, CD4+ T cells commit to the Th1 path — mounting antiviral and antibacterial responses that suppress IgE production and eosinophil activation. When T-bet is constrained, the Th2 program fills the vacuum, priming the immune system for IgE-mediated allergic inflammation. rs11650354 is an intronic variant within TBX21 that, together with the neighboring downstream variant rs16947078, defines a risk haplotype strongly associated with allergic asthma in European-ancestry children. Carriers of the T allele — and especially TT homozygotes — appear to carry reduced Th1 tone at this locus, tilting the immune system toward the Th2 phenotype underpinning allergic airway disease.

The Mechanism

rs11650354 lies within an intron of TBX21. It does not alter the T-bet protein sequence — there is no amino acid change or splice disruption. Its functional significance is regulatory: the T allele is thought to influence how TBX21 is expressed in T-lymphocyte subsets, reducing the quantity of T-bet available to enforce Th1 polarization. The exact intronic regulatory element has not been functionally characterized in isolation, but the variant overlaps with [open chromatin regions accessible in T cells | eQTL data in the TBX21-TBKBP1 locus identify rs11650354 as lying within chromatin accessible to transcription factor binding in lymphocyte cell lines], suggesting it resides within an active regulatory element influencing transcriptional output. When T-bet output is reduced, the transcriptional repression of GATA3 and other Th2-promoting regulators weakens, allowing the Th2 program to predominate. The downstream consequences are increased IgE class-switching, mast cell and eosinophil priming, and heightened airway reactivity — the hallmarks of allergic asthma. The systemic sclerosis data²² systemic sclerosis data
Kariuki et al. 2010 showed TT carriers have elevated serum IL-4, IL-5, and IL-13 levels compared to CC homozygotes, directly demonstrating the Th2 cytokine excess associated with TT genotype provides functional support: TT homozygotes show measurably elevated Th2 cytokines (IL-4, IL-5, IL-13) versus CC carriers, consistent with reduced T-bet suppression of the Th2 effector program.

The Evidence

The primary evidence for allergic asthma association comes from the 2008 Munthe-Kaas et al. study³³ 2008 Munthe-Kaas et al. study
948 children from the Environment and Childhood Asthma (ECA) cohort, Norway; 12 TBX21-region SNPs genotyped; outcomes assessed at age 10 including allergic asthma, non-allergic asthma, spirometry, methacholine challenge, FeNO, and IgE. Two SNPs — rs11650354 and rs16947078 — showed significant independent associations with allergic asthma, and the risk haplotype containing both variants carried a striking [odds ratio of 8.3 (95% CI 2.5–26.9) | The wide confidence interval reflects the rarity of homozygous risk haplotype carriers in the study cohort; the point estimate is large but should be interpreted with appropriate caution pending larger replication studies in independent European cohorts] for allergic asthma in homozygous carriers. Critically, the association was specific to allergic asthma — not to non-allergic asthma or allergy alone — consistent with a mechanism acting on the IgE-mediated arm of the Th2 response.

Functional evidence linking the T allele to Th2 cytokine excess comes from the Kariuki et al. 2010 systemic sclerosis study⁴⁴ Kariuki et al. 2010 systemic sclerosis study
902 SSc patients, 4,745 controls; North American white population; TT genotype OR 3.37, P=1.4×10⁻¹⁵; functional cytokine profiling showed TT carriers elevated in IL-4, IL-5, IL-13. TT homozygotes showed elevated serum Th2 cytokines, directly confirming the predicted biological consequence of reduced T-bet activity at this locus. A 2009 German study⁵⁵ 2009 German study
Suttner et al.; 43 TBX21 polymorphisms in German children; three tagging SNPs increased childhood asthma risk with ORs 1.39–2.60; TBX21 combined with HLX1 variants gave >3-fold increased asthma risk in a gene-risk-score model confirmed that TBX21 variants, likely including the rs11650354 haplotype block, increase childhood asthma risk, and that TBX21 interacts with HLX1 (another T-cell transcription factor gene) to amplify asthma risk beyond either gene alone.

The association is predominantly observed in European-ancestry populations, where the T allele frequency is approximately 18%. It is substantially rarer in East Asian populations (~3.5%), which may explain why studies in Korean and other Asian cohorts have not replicated this signal — the low T allele frequency makes power to detect TT homozygote effects very limited in these cohorts.

Practical Actions

For CT heterozygotes, the T allele adds marginal directional risk within the haplotype context; early symptom awareness and targeted allergen management are the primary practical implications. TT homozygotes, though rare (~2.7% globally, ~3% in Europeans), carry a genuinely elevated allergic asthma risk from both alleles and warrant proactive respiratory evaluation.

The reduced T-bet tone that the T allele appears to confer means the Th1 brake on Th2 responses is less effective — the same allergen load elicits a stronger IgE and eosinophil response than in CC individuals. Reducing indoor allergen exposure directly addresses this vulnerability. Early spirometry and IgE assessment establish objective baselines before airway remodeling occurs, supporting earlier intervention if asthma develops.

Interactions

rs11650354 and rs16947078 together constitute the TBX21 risk haplotype identified in the Munthe-Kaas 2008 study. Carriers of the T allele at rs11650354 are at meaningfully higher risk if they also carry the G allele at rs16947078 — the two variants act in the same haplotype block and their co-inheritance is what defines the OR 8.3 effect seen for haplotype homozygosity. A third TBX21 variant, rs4794067 (upstream regulatory, associated with aspirin-induced asthma and nasal polyps), operates through a distinct regulatory entry point at the 5-prime end of TBX21 and compounds T-bet deficiency when co-inherited with the rs11650354 / rs16947078 haplotype. The TBX21 + HLX1 interaction identified by Suttner et al. suggests that TBX21 risk alleles also interact with variants in other Th1/Th2 transcription factor genes beyond the TBX21 locus itself.